Cite
Greater Combined Reductions of HbA1c ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators
MLA
Kathleen M. Dungan, et al. “Greater Combined Reductions of HbA1c ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators.” Diabetes Therapy, May 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f4bc9a514bf2b1c0eee6f5f434a748b2&authtype=sso&custid=ns315887.
APA
Kathleen M. Dungan, Lars Bardtrum, Erik Christiansen, Johanna Eliasson, Linda Mellbin, Vincent C. Woo, & Tina Vilsbøll. (2023). Greater Combined Reductions of HbA1c ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators. Diabetes Therapy.
Chicago
Kathleen M. Dungan, Lars Bardtrum, Erik Christiansen, Johanna Eliasson, Linda Mellbin, Vincent C. Woo, and Tina Vilsbøll. 2023. “Greater Combined Reductions of HbA1c ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators.” Diabetes Therapy, May. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f4bc9a514bf2b1c0eee6f5f434a748b2&authtype=sso&custid=ns315887.